Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

443.25 +6.98 (+1.60%)
Streaming Delayed Price Updated: 10:27 AM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
News headline image
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Global Markets Brace for Inflation's Enduring Grip: A November 2025 Outlook
As November 2025 unfolds, global financial markets find themselves in a complex and challenging environment, bracing for the enduring grip of inflation. Despite some signs of moderating headline... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs. 
Via Benzinga
News headline image
2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that... 
Via StockStory
News headline image
Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday? ↗
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date... 
Via Benzinga
News headline image
VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was... 
Via StockStory
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was... 
Via StockStory
News headline image
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book ↗
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost. 
Via Investor's Business Daily
News headline image
Vertex Reports Third Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
Nvidia, Amazon Extend Rally, Bitcoin Sinks To $107,000: What's Moving Markets Monday? ↗
Wall Street opened the week on a mixed note on Monday. 
Via Benzinga
News headline image
2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon ↗
These healthcare stocks are making strides in very important ways. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years? ↗
These are great picks with or without soaring inflation. 
Via The Motley Fool
Topics Economy Government World Trade
News headline image
My Top Growth Stock to Buy in November ↗
This stock isn't bulletproof. But it should be a big winner over the coming years. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know. 
Via StockStory
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
Via MarketBeat
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Bullish Technical Setup ↗
Discover how Vertex Pharmaceuticals (VRTX) combines strong fundamentals, like high profitability and no debt, with a bullish technical breakout pattern for potential growth. 
Via Chartmill
News headline image
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These ↗
These two have been neglected by Wall Street too much. 
Via The Motley Fool
News headline image
Vertex to Participate in the UBS Global Healthcare Conference on November 11
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030 ↗
Vertex appears to be by far the better buy right now. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Best Stocks to Invest $50,000 In Right Now ↗
There's no guarantee that any stock will deliver positive returns. But the odds look good for these three. 
Via The Motley Fool
Topics Artificial Intelligence Energy
News headline image
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Value Investment Case Study ↗
Vertex Pharmaceuticals (VRTX) presents a value investing case with strong profitability, a debt-free balance sheet, and a valuation that appears attractive relative to its industry peers. 
Via Chartmill
News headline image
2 Growth Stocks to Invest $1,000 in Right Now ↗
These companies have a habit of beating the market, and they are far from having peaked. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
News headline image
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Soaring Cathie Wood Stocks to Buy and Hold ↗
These companies' market-beating fuel hasn't run out yet. 
Via The Motley Fool
News headline image
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market ↗
Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.